1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Chemotherapy 1.2.3 Immunotherapy 1.2.4 Targeted Therapy 1.2.5 Radiotherapy 1.2.6 Stem Cell Transplantation 1.2.7 Others 1.3 Market by Application 1.3.1 Global Hematological Malignancies Disease Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Leukemia 1.3.3 Lymphoma 1.3.4 Myeloma 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Hematological Malignancies Disease Market Perspective (2016-2027) 2.2 Hematological Malignancies Disease Growth Trends by Regions 2.2.1 Hematological Malignancies Disease Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Hematological Malignancies Disease Historic Market Share by Regions (2016-2021) 2.2.3 Hematological Malignancies Disease Forecasted Market Size by Regions (2022-2027) 2.3 Hematological Malignancies Disease Industry Dynamic 2.3.1 Hematological Malignancies Disease Market Trends 2.3.2 Hematological Malignancies Disease Market Drivers 2.3.3 Hematological Malignancies Disease Market Challenges 2.3.4 Hematological Malignancies Disease Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hematological Malignancies Disease Players by Revenue 3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2016-2021) 3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2016-2021) 3.2 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Hematological Malignancies Disease Revenue 3.4 Global Hematological Malignancies Disease Market Concentration Ratio 3.4.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2020 3.5 Hematological Malignancies Disease Key Players Head office and Area Served 3.6 Key Players Hematological Malignancies Disease Product Solution and Service 3.7 Date of Enter into Hematological Malignancies Disease Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hematological Malignancies Disease Breakdown Data by Type 4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2016-2021) 4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2022-2027) 5 Hematological Malignancies Disease Breakdown Data by Application 5.1 Global Hematological Malignancies Disease Historic Market Size by Application (2016-2021) 5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Hematological Malignancies Disease Market Size (2016-2027) 6.2 North America Hematological Malignancies Disease Market Size by Type 6.2.1 North America Hematological Malignancies Disease Market Size by Type (2016-2021) 6.2.2 North America Hematological Malignancies Disease Market Size by Type (2022-2027) 6.2.3 North America Hematological Malignancies Disease Market Size by Type (2016-2027) 6.3 North America Hematological Malignancies Disease Market Size by Application 6.3.1 North America Hematological Malignancies Disease Market Size by Application (2016-2021) 6.3.2 North America Hematological Malignancies Disease Market Size by Application (2022-2027) 6.3.3 North America Hematological Malignancies Disease Market Size by Application (2016-2027) 6.4 North America Hematological Malignancies Disease Market Size by Country 6.4.1 North America Hematological Malignancies Disease Market Size by Country (2016-2021) 6.4.2 North America Hematological Malignancies Disease Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Hematological Malignancies Disease Market Size (2016-2027) 7.2 Europe Hematological Malignancies Disease Market Size by Type 7.2.1 Europe Hematological Malignancies Disease Market Size by Type (2016-2021) 7.2.2 Europe Hematological Malignancies Disease Market Size by Type (2022-2027) 7.2.3 Europe Hematological Malignancies Disease Market Size by Type (2016-2027) 7.3 Europe Hematological Malignancies Disease Market Size by Application 7.3.1 Europe Hematological Malignancies Disease Market Size by Application (2016-2021) 7.3.2 Europe Hematological Malignancies Disease Market Size by Application (2022-2027) 7.3.3 Europe Hematological Malignancies Disease Market Size by Application (2016-2027) 7.4 Europe Hematological Malignancies Disease Market Size by Country 7.4.1 Europe Hematological Malignancies Disease Market Size by Country (2016-2021) 7.4.2 Europe Hematological Malignancies Disease Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Hematological Malignancies Disease Market Size (2016-2027) 8.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type 8.2.1 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2027) 8.3 Asia-Pacific Hematological Malignancies Disease Market Size by Application 8.3.1 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2027) 8.4 Asia-Pacific Hematological Malignancies Disease Market Size by Region 8.4.1 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Hematological Malignancies Disease Market Size (2016-2027) 9.2 Latin America Hematological Malignancies Disease Market Size by Type 9.2.1 Latin America Hematological Malignancies Disease Market Size by Type (2016-2021) 9.2.2 Latin America Hematological Malignancies Disease Market Size by Type (2022-2027) 9.2.3 Latin America Hematological Malignancies Disease Market Size by Type (2016-2027) 9.3 Latin America Hematological Malignancies Disease Market Size by Application 9.3.1 Latin America Hematological Malignancies Disease Market Size by Application (2016-2021) 9.3.2 Latin America Hematological Malignancies Disease Market Size by Application (2022-2027) 9.3.3 Latin America Hematological Malignancies Disease Market Size by Application (2016-2027) 9.4 Latin America Hematological Malignancies Disease Market Size by Country 9.4.1 Latin America Hematological Malignancies Disease Market Size by Country (2016-2021) 9.4.2 Latin America Hematological Malignancies Disease Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Hematological Malignancies Disease Market Size (2016-2027) 10.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type 10.2.1 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2027) 10.3 Middle East & Africa Hematological Malignancies Disease Market Size by Application 10.3.1 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2027) 10.4 Middle East & Africa Hematological Malignancies Disease Market Size by Country 10.4.1 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Affymetrix 11.1.1 Affymetrix Company Details 11.1.2 Affymetrix Business Overview 11.1.3 Affymetrix Hematological Malignancies Disease Introduction 11.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2016-2021) 11.1.5 Affymetrix Recent Development 11.2 SkylineDx 11.2.1 SkylineDx Company Details 11.2.2 SkylineDx Business Overview 11.2.3 SkylineDx Hematological Malignancies Disease Introduction 11.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2016-2021) 11.2.5 SkylineDx Recent Development 11.3 AgenaBio 11.3.1 AgenaBio Company Details 11.3.2 AgenaBio Business Overview 11.3.3 AgenaBio Hematological Malignancies Disease Introduction 11.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2016-2021) 11.3.5 AgenaBio Recent Development 11.4 Signal Genetics 11.4.1 Signal Genetics Company Details 11.4.2 Signal Genetics Business Overview 11.4.3 Signal Genetics Hematological Malignancies Disease Introduction 11.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2016-2021) 11.4.5 Signal Genetics Recent Development 11.5 Pfizer 11.5.1 Pfizer Company Details 11.5.2 Pfizer Business Overview 11.5.3 Pfizer Hematological Malignancies Disease Introduction 11.5.4 Pfizer Revenue in Hematological Malignancies Disease Business (2016-2021) 11.5.5 Pfizer Recent Development 11.6 Roche 11.6.1 Roche Company Details 11.6.2 Roche Business Overview 11.6.3 Roche Hematological Malignancies Disease Introduction 11.6.4 Roche Revenue in Hematological Malignancies Disease Business (2016-2021) 11.6.5 Roche Recent Development 11.7 Sanofi-Aventis 11.7.1 Sanofi-Aventis Company Details 11.7.2 Sanofi-Aventis Business Overview 11.7.3 Sanofi-Aventis Hematological Malignancies Disease Introduction 11.7.4 Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2016-2021) 11.7.5 Sanofi-Aventis Recent Development 11.8 Cancer Genetics Inc 11.8.1 Cancer Genetics Inc Company Details 11.8.2 Cancer Genetics Inc Business Overview 11.8.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction 11.8.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2016-2021) 11.8.5 Cancer Genetics Inc Recent Development 11.9 Illumina 11.9.1 Illumina Company Details 11.9.2 Illumina Business Overview 11.9.3 Illumina Hematological Malignancies Disease Introduction 11.9.4 Illumina Revenue in Hematological Malignancies Disease Business (2016-2021) 11.9.5 Illumina Recent Development 11.10 NeoGenomics 11.10.1 NeoGenomics Company Details 11.10.2 NeoGenomics Business Overview 11.10.3 NeoGenomics Hematological Malignancies Disease Introduction 11.10.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2016-2021) 11.10.5 NeoGenomics Recent Development 11.11 Exiqon 11.11.1 Exiqon Company Details 11.11.2 Exiqon Business Overview 11.11.3 Exiqon Hematological Malignancies Disease Introduction 11.11.4 Exiqon Revenue in Hematological Malignancies Disease Business (2016-2021) 11.11.5 Exiqon Recent Development 11.12 Regulus Therapeutics 11.12.1 Regulus Therapeutics Company Details 11.12.2 Regulus Therapeutics Business Overview 11.12.3 Regulus Therapeutics Hematological Malignancies Disease Introduction 11.12.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2016-2021) 11.12.5 Regulus Therapeutics Recent Development 11.13 Rosetta Genomics 11.13.1 Rosetta Genomics Company Details 11.13.2 Rosetta Genomics Business Overview 11.13.3 Rosetta Genomics Hematological Malignancies Disease Introduction 11.13.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2016-2021) 11.13.5 Rosetta Genomics Recent Development 11.14 Sequenta 11.14.1 Sequenta Company Details 11.14.2 Sequenta Business Overview 11.14.3 Sequenta Hematological Malignancies Disease Introduction 11.14.4 Sequenta Revenue in Hematological Malignancies Disease Business (2016-2021) 11.14.5 Sequenta Recent Development 11.15 Takeda Pharma 11.15.1 Takeda Pharma Company Details 11.15.2 Takeda Pharma Business Overview 11.15.3 Takeda Pharma Hematological Malignancies Disease Introduction 11.15.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) 11.15.5 Takeda Pharma Recent Development 11.16 Celgene 11.16.1 Celgene Company Details 11.16.2 Celgene Business Overview 11.16.3 Celgene Hematological Malignancies Disease Introduction 11.16.4 Celgene Revenue in Hematological Malignancies Disease Business (2016-2021) 11.16.5 Celgene Recent Development 11.17 Amgen 11.17.1 Amgen Company Details 11.17.2 Amgen Business Overview 11.17.3 Amgen Hematological Malignancies Disease Introduction 11.17.4 Amgen Revenue in Hematological Malignancies Disease Business (2016-2021) 11.17.5 Amgen Recent Development 11.18 Ono Pharma 11.18.1 Ono Pharma Company Details 11.18.2 Ono Pharma Business Overview 11.18.3 Ono Pharma Hematological Malignancies Disease Introduction 11.18.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) 11.18.5 Ono Pharma Recent Development 11.18 Abbott .1 Abbott Company Details .2 Abbott Business Overview .3 Abbott Hematological Malignancies Disease Introduction .4 Abbott Revenue in Hematological Malignancies Disease Business (2016-2021) .5 Abbott Recent Development 11.20 BMS 11.20.1 BMS Company Details 11.20.2 BMS Business Overview 11.20.3 BMS Hematological Malignancies Disease Introduction 11.20.4 BMS Revenue in Hematological Malignancies Disease Business (2016-2021) 11.20.5 BMS Recent Development 11.21 Mundipharma 11.21.1 Mundipharma Company Details 11.21.2 Mundipharma Business Overview 11.21.3 Mundipharma Hematological Malignancies Disease Introduction 11.21.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2016-2021) 11.21.5 Mundipharma Recent Development 11.22 Novartis 11.22.1 Novartis Company Details 11.22.2 Novartis Business Overview 11.22.3 Novartis Hematological Malignancies Disease Introduction 11.22.4 Novartis Revenue in Hematological Malignancies Disease Business (2016-2021) 11.22.5 Novartis Recent Development 11.23 MorphoSys 11.23.1 MorphoSys Company Details 11.23.2 MorphoSys Business Overview 11.23.3 MorphoSys Hematological Malignancies Disease Introduction 11.23.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2016-2021) 11.23.5 MorphoSys Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hematological Malignancies Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Chemotherapy Table 3. Key Players of Immunotherapy Table 4. Key Players of Targeted Therapy Table 5. Key Players of Radiotherapy Table 6. Key Players of Stem Cell Transplantation Table 7. Key Players of Others Table 8. Global Hematological Malignancies Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global Hematological Malignancies Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Hematological Malignancies Disease Market Size by Regions (2016-2021) & (US$ Million) Table 11. Global Hematological Malignancies Disease Market Share by Regions (2016-2021) Table 12. Global Hematological Malignancies Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 13. Global Hematological Malignancies Disease Market Share by Regions (2022-2027) Table 14. Hematological Malignancies Disease Market Trends Table 15. Hematological Malignancies Disease Market Drivers Table 16. Hematological Malignancies Disease Market Challenges Table 17. Hematological Malignancies Disease Market Restraints Table 18. Global Hematological Malignancies Disease Revenue by Players (2016-2021) & (US$ Million) Table 19. Global Hematological Malignancies Disease Market Share by Players (2016-2021) Table 20. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2020) Table 21. Ranking of Global Top Hematological Malignancies Disease Companies by Revenue (US$ Million) in 2020 Table 22. Global 5 Largest Players Market Share by Hematological Malignancies Disease Revenue (CR5 and HHI) & (2016-2021) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Hematological Malignancies Disease Product Solution and Service Table 25. Date of Enter into Hematological Malignancies Disease Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 28. Global Hematological Malignancies Disease Revenue Market Share by Type (2016-2021) Table 29. Global Hematological Malignancies Disease Forecasted Market Size by Type (2022-2027) (US$ Million) Table 30. Global Hematological Malignancies Disease Revenue Market Share by Type (2022-2027) & (US$ Million) Table 31. Global Hematological Malignancies Disease Market Size Share by Application (2016-2021) & (US$ Million) Table 32. Global Hematological Malignancies Disease Revenue Market Share by Application (2016-2021) Table 33. Global Hematological Malignancies Disease Forecasted Market Size by Application (2022-2027) (US$ Million) Table 34. Global Hematological Malignancies Disease Revenue Market Share by Application (2022-2027) & (US$ Million) Table 35. North America Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 36. North America Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million) Table 37. North America Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million) Table 38. North America Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million) Table 39. North America Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million) Table 40. North America Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million) Table 41. Europe Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 42. Europe Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million) Table 43. Europe Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million) Table 44. Europe Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million) Table 45. Europe Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million) Table 46. Europe Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million) Table 47. Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 48. Asia-Pacific Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million) Table 49. Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million) Table 50. Asia-Pacific Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million) Table 51. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2016-2021) & (US$ Million) Table 52. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2022-2027) & (US$ Million) Table 53. Latin America Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 54. Latin America Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million) Table 55. Latin America Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million) Table 56. Latin America Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million) Table 57. Latin America Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million) Table 58. Latin America Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million) Table 59. Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million) Table 60. Middle East & Africa Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million) Table 61. Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million) Table 62. Middle East & Africa Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million) Table 63. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million) Table 64. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million) Table 65. Affymetrix Company Details Table 66. Affymetrix Business Overview Table 67. Affymetrix Hematological Malignancies Disease Product Table 68. Affymetrix Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 69. Affymetrix Recent Development Table 70. SkylineDx Company Details Table 71. SkylineDx Business Overview Table 72. SkylineDx Hematological Malignancies Disease Product Table 73. SkylineDx Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 74. SkylineDx Recent Development Table 75. AgenaBio Company Details Table 76. AgenaBio Business Overview Table 77. AgenaBio Hematological Malignancies Disease Product Table 78. AgenaBio Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 79. AgenaBio Recent Development Table 80. Signal Genetics Company Details Table 81. Signal Genetics Business Overview Table 82. Signal Genetics Hematological Malignancies Disease Product Table 83. Signal Genetics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 84. Signal Genetics Recent Development Table 85. Pfizer Company Details Table 86. Pfizer Business Overview Table 87. Pfizer Hematological Malignancies Disease Product Table 88. Pfizer Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 89. Pfizer Recent Development Table 90. Roche Company Details Table 91. Roche Business Overview Table 92. Roche Hematological Malignancies Disease Product Table 93. Roche Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 94. Roche Recent Development Table 95. Sanofi-Aventis Company Details Table 96. Sanofi-Aventis Business Overview Table 97. Sanofi-Aventis Hematological Malignancies Disease Product Table 98. Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 99. Sanofi-Aventis Recent Development Table 100. Cancer Genetics Inc Company Details Table 101. Cancer Genetics Inc Business Overview Table 102. Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 103. Cancer Genetics Inc Recent Development Table 104. Illumina Company Details Table 105. Illumina Business Overview Table 106. Illumina Hematological Malignancies Disease Product Table 107. Illumina Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 108. Illumina Recent Development Table 109. NeoGenomics Company Details Table 110. NeoGenomics Business Overview Table 111. NeoGenomics Hematological Malignancies Disease Product Table 112. NeoGenomics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 113. NeoGenomics Recent Development Table 114. Exiqon Company Details Table 115. Exiqon Business Overview Table 116. Exiqon Hematological Malignancies Disease Product Table 117. Exiqon Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 118. Exiqon Recent Development Table 119. Regulus Therapeutics Company Details Table 120. Regulus Therapeutics Business Overview Table 121. Regulus Therapeutics Hematological Malignancies Disease Product Table 122. Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 123. Regulus Therapeutics Recent Development Table 124. Rosetta Genomics Company Details Table 125. Rosetta Genomics Business Overview Table 126. Rosetta Genomics Hematological Malignancies Disease Product Table 127. Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 128. Rosetta Genomics Recent Development Table 129. Sequenta Company Details Table 130. Sequenta Business Overview Table 131. Sequenta Hematological Malignancies Disease Product Table 132. Sequenta Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 133. Sequenta Recent Development Table 134. Takeda Pharma Company Details Table 135. Takeda Pharma Business Overview Table 136. Takeda Pharma Hematological Malignancies Disease Product Table 137. Takeda Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 138. Takeda Pharma Recent Development Table 139. Celgene Company Details Table 140. Celgene Business Overview Table 141. Celgene Hematological Malignancies Disease Product Table 142. Celgene Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 143. Celgene Recent Development Table 144. Amgen Company Details Table 145. Amgen Business Overview Table 146. Amgen Hematological Malignancies Disease Product Table 147. Amgen Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 148. Amgen Recent Development Table 149. Ono Pharma Company Details Table 150. Ono Pharma Business Overview Table 151. Ono Pharma Hematological Malignancies Disease Product Table 152. Ono Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 153. Ono Pharma Recent Development Table 154. Abbott Company Details Table 155. Abbott Business Overview Table 156. Abbott Hematological Malignancies Disease Product Table 157. Abbott Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 158. Abbott Recent Development Table 159. BMS Company Details Table 160. BMS Business Overview Table 161. BMS Hematological Malignancies Disease Product Table 162. BMS Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 163. BMS Recent Development Table 164. Mundipharma Company Details Table 165. Mundipharma Business Overview Table 166. Mundipharma Hematological Malignancies Disease Product Table 167. Mundipharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 168. Mundipharma Recent Development Table 169. Novartis Company Details Table 170. Novartis Business Overview Table 171. Novartis Hematological Malignancies Disease Product Table 172. Novartis Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 173. Novartis Recent Development Table 174. MorphoSys Company Details Table 175. MorphoSys Business Overview Table 176. MorphoSys Hematological Malignancies Disease Product Table 177. MorphoSys Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million) Table 178. MorphoSys Recent Development Table 179. Research Programs/Design for This Report Table 180. Key Data Information from Secondary Sources Table 181. Key Data Information from Primary Sources List of Figures Figure 1. Global Hematological Malignancies Disease Market Share by Type: 2020 VS 2027 Figure 2. Chemotherapy Features Figure 3. Immunotherapy Features Figure 4. Targeted Therapy Features Figure 5. Radiotherapy Features Figure 6. Stem Cell Transplantation Features Figure 7. Others Features Figure 8. Global Hematological Malignancies Disease Market Share by Application: 2020 VS 2027 Figure 9. Leukemia Case Studies Figure 10. Lymphoma Case Studies Figure 11. Myeloma Case Studies Figure 12. Others Case Studies Figure 13. Hematological Malignancies Disease Report Years Considered Figure 14. Global Hematological Malignancies Disease Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 15. Global Hematological Malignancies Disease Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 16. Global Hematological Malignancies Disease Market Share by Regions: 2020 VS 2027 Figure 17. Global Hematological Malignancies Disease Market Share by Regions (2022-2027) Figure 18. Global Hematological Malignancies Disease Market Share by Players in 2020 Figure 19. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2020 Figure 20. The Top 10 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2020 Figure 21. Global Hematological Malignancies Disease Revenue Market Share by Type (2016-2021) Figure 22. Global Hematological Malignancies Disease Revenue Market Share by Type (2022-2027) Figure 23. North America Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. North America Hematological Malignancies Disease Market Share by Type (2016-2027) Figure 25. North America Hematological Malignancies Disease Market Share by Application (2016-2027) Figure 26. North America Hematological Malignancies Disease Market Share by Country (2016-2027) Figure 27. United States Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Canada Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Europe Hematological Malignancies Disease Market Share by Type (2016-2027) Figure 31. Europe Hematological Malignancies Disease Market Share by Application (2016-2027) Figure 32. Europe Hematological Malignancies Disease Market Share by Country (2016-2027) Figure 33. Germany Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. France Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. U.K. Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Italy Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Russia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Nordic Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Asia-Pacific Hematological Malignancies Disease Market Share by Type (2016-2027) Figure 41. Asia-Pacific Hematological Malignancies Disease Market Share by Application (2016-2027) Figure 42. Asia-Pacific Hematological Malignancies Disease Market Share by Region (2016-2027) Figure 43. China Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Japan Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. South Korea Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Southeast Asia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. India Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Australia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Latin America Hematological Malignancies Disease Market Share by Type (2016-2027) Figure 51. Latin America Hematological Malignancies Disease Market Share by Application (2016-2027) Figure 52. Latin America Hematological Malignancies Disease Market Share by Country (2016-2027) Figure 53. Mexico Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Brazil Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Middle East & Africa Hematological Malignancies Disease Market Share by Type (2016-2027) Figure 57. Middle East & Africa Hematological Malignancies Disease Market Share by Application (2016-2027) Figure 58. Middle East & Africa Hematological Malignancies Disease Market Share by Country (2016-2027) Figure 59. Turkey Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. Saudi Arabia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. UAE Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Affymetrix Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 63. SkylineDx Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 64. AgenaBio Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 65. Signal Genetics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 66. Pfizer Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 67. Roche Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 68. Sanofi-Aventis Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 69. Cancer Genetics Inc Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 70. Illumina Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 71. NeoGenomics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 72. Exiqon Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 73. Regulus Therapeutics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 74. Rosetta Genomics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 75. Sequenta Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 76. Takeda Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 77. Celgene Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 78. Amgen Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 79. Ono Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 80. Abbott Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 81. BMS Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 82. Mundipharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 83. Novartis Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 84. MorphoSys Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021) Figure 85. Bottom-up and Top-down Approaches for This Report Figure 86. Data Triangulation Figure 87. Key Executives Interviewed

Affymetrix SkylineDx AgenaBio Signal Genetics Pfizer Roche Sanofi-Aventis Cancer Genetics Inc Illumina NeoGenomics Exiqon Regulus Therapeutics Rosetta Genomics Sequenta Takeda Pharma Celgene Amgen Ono Pharma Abbott BMS Mundipharma Novartis MorphoSys